• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    1/9/23 12:30:53 PM ET
    $ALBO
    $AMYT
    $APGN
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALBO alert in real time by email

    Gainers

    • CinCor Pharma (NASDAQ:CINC) shares increased by 148.0% to $29.22 during Monday's regular session. As of 12:30 EST, CinCor Pharma's stock is trading at a volume of 7.1 million, which is 1750.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $1.2 billion.
    • Amryt Pharma (NASDAQ:AMYT) stock moved upwards by 109.14% to $14.64. Trading volume for Amryt Pharma's stock is 9.9 million as of 12:30 EST. This is 22502.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $936.5 million.
    • Apexigen (NASDAQ:APGN) stock moved upwards by 108.54% to $1.83. The current volume of 67.7 million shares is 183896.1% of Apexigen's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $41.2 million.
    • Albireo Pharma (NASDAQ:ALBO) shares moved upwards by 92.46% to $43.92. The current volume of 4.6 million shares is 2164.0% of Albireo Pharma's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $909.2 million.
    • G Medical Innovations (NASDAQ:GMVD) stock rose 89.58% to $5.46. As of 12:30 EST, this security is trading at a volume of 5.5 million shares, making up 13078.9% of its average full-day volume over the last 100 days. The company's market cap stands at $5.4 million.
    • Revance Therapeutics (NASDAQ:RVNC) stock increased by 43.88% to $28.36. Revance Therapeutics's stock is trading at a volume of 5.4 million shares as of 12:30 EST. This is 443.3% of its average full-day volume over the last 100 days. The company's market cap stands at $2.3 billion.

    Losers

    • Calithera Biosciences (NASDAQ:CALA) stock fell 81.3% to $0.68 during Monday's regular session. As of 12:30 EST, Calithera Biosciences's stock is trading at a volume of 3.8 million, which is 7402.1% of its average full-day volume over the last 100 days. The company's market cap stands at $3.2 million.
    • Peak Bio (NASDAQ:PKBO) shares fell 27.99% to $2.54. The current volume of 78.4K shares is 15.0% of Peak Bio's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $50.8 million.
    • Cutera (NASDAQ:CUTR) shares fell 23.54% to $30.93. The current volume of 1.7 million shares is 540.4% of Cutera's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $606.7 million.
    • Cerus (NASDAQ:CERS) shares fell 22.62% to $2.92. Cerus's stock is trading at a volume of 3.3 million shares as of 12:30 EST. This is 297.3% of its average full-day volume over the last 100 days. The company's market cap stands at $518.9 million.
    • Ontrak (NASDAQ:OTRKP) shares fell 20.1% to $0.43.
    • Arrowhead Pharma (NASDAQ:ARWR) stock fell 19.68% to $30.02. The current volume of 1.9 million shares is 222.8% of Arrowhead Pharma's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $3.4 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALBO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALBO
    $AMYT
    $APGN
    $ARWR

    CompanyDatePrice TargetRatingAnalyst
    Arrowhead Pharmaceuticals Inc.
    $ARWR
    6/5/2024$31.00Neutral
    Goldman
    Cerus Corporation
    $CERS
    4/12/2024$5.00Buy
    Craig Hallum
    Cutera Inc.
    $CUTR
    3/22/2024Underperform → Mkt Perform
    William Blair
    Revance Therapeutics Inc.
    $RVNC
    1/29/2024$16.00 → $9.00Buy → Neutral
    Mizuho
    Revance Therapeutics Inc.
    $RVNC
    1/9/2024$30.00 → $8.00Buy → Neutral
    Goldman
    Arrowhead Pharmaceuticals Inc.
    $ARWR
    12/4/2023$29.00Buy
    BofA Securities
    Arrowhead Pharmaceuticals Inc.
    $ARWR
    9/19/2023$33.00Neutral
    Citigroup
    Revance Therapeutics Inc.
    $RVNC
    8/16/2023$20.00Underperform → Neutral
    Exane BNP Paribas
    More analyst ratings

    $ALBO
    $AMYT
    $APGN
    $ARWR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

    2025 Total Revenue of $233.8 million, up 16% from 2024; 2025 Product Revenue of $206.1 million, up 14% from 2024 Strengthened Financial Foundation Through Strong Commercial Execution and Disciplined Operational Management Cerus Corporation (NASDAQ:CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. "Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components," said William "Obi" Greenman, Cerus' pres

    3/2/26 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026 Type: Fireside Chat Presentation Date/Time: March 2, 2026, 11:50 a.m. EST Leerink 2026 Global Healthcare Conference – March 8-11, 2026 Type: Fireside Chat Presentation Date/Time: March 9, 2026, 2:20 p.m. EST 2026 Jefferies Biotech on the Beach Summit – March 9-11, 2026 Type: Investor Group Dinner Date/Time: March 9, 2026 Type: Investor 1x1 Meetings Date/Time: March 11, 2026 Barclays 28th Annual Global Healthcare Conference – March 10-12, 2026 Type: Investor 1x1 Meetings Date/Time: M

    2/24/26 7:30:00 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cerus Corporation to Participate in the TD Cowen 46th Annual Health Care Conference

    Cerus Corporation (NASDAQ:CERS) announced today that members of the Company's management are scheduled to present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m. EST. A live webcast of the fireside chat will be accessible through the Investor Relations page of the Cerus website at http://www.cerus.com/ir. A replay will be available for 90 days after the event. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components

    2/20/26 8:30:00 AM ET
    $CERS
    EDP Services
    Technology

    $ALBO
    $AMYT
    $APGN
    $ARWR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gregory Dean A. bought $31,250 worth of shares (25,000 units at $1.25), increasing direct ownership by 41% to 86,725 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    8/25/25 3:25:00 PM ET
    $CERS
    EDP Services
    Technology

    Director Gregory Dean A. bought $2,932 worth of shares (1,725 units at $1.70), increasing direct ownership by 3% to 61,725 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    1/2/25 5:46:11 PM ET
    $CERS
    EDP Services
    Technology

    Shan Hua bought $4,975 worth of shares (2,500 units at $1.99), increasing direct ownership by 8% to 32,386 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    5/14/24 6:30:46 PM ET
    $CERS
    EDP Services
    Technology

    $ALBO
    $AMYT
    $APGN
    $ARWR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Arrowhead with a new price target

    Goldman initiated coverage of Arrowhead with a rating of Neutral and set a new price target of $31.00

    6/5/24 7:11:50 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum initiated coverage on Cerus with a new price target

    Craig Hallum initiated coverage of Cerus with a rating of Buy and set a new price target of $5.00

    4/12/24 8:00:30 AM ET
    $CERS
    EDP Services
    Technology

    Cutera upgraded by William Blair

    William Blair upgraded Cutera from Underperform to Mkt Perform

    3/22/24 7:28:54 AM ET
    $CUTR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ALBO
    $AMYT
    $APGN
    $ARWR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Medical Officer Benjamin Richard J was granted 55,220 shares and sold $250,932 worth of shares (125,894 units at $1.99), decreasing direct ownership by 7% to 879,101 units (SEC Form 4)

    4/A - CERUS CORP (0001020214) (Issuer)

    3/10/26 7:05:49 AM ET
    $CERS
    EDP Services
    Technology

    Chief Financial Officer Green Kevin Dennis was granted 63,854 shares and sold $169,646 worth of shares (83,021 units at $2.04), decreasing direct ownership by 2% to 1,168,095 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    3/9/26 9:56:38 PM ET
    $CERS
    EDP Services
    Technology

    Chief Medical Officer Benjamin Richard J was granted 55,220 shares and sold $250,938 worth of shares (125,894 units at $1.99), decreasing direct ownership by 7% to 879,101 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    3/9/26 9:35:51 PM ET
    $CERS
    EDP Services
    Technology

    $ALBO
    $AMYT
    $APGN
    $ARWR
    SEC Filings

    View All

    SEC Form 144 filed by Cerus Corporation

    144 - CERUS CORP (0001020214) (Subject)

    3/5/26 5:03:03 PM ET
    $CERS
    EDP Services
    Technology

    SEC Form 10-K filed by Cerus Corporation

    10-K - CERUS CORP (0001020214) (Filer)

    3/2/26 5:03:45 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CERUS CORP (0001020214) (Filer)

    3/2/26 4:03:18 PM ET
    $CERS
    EDP Services
    Technology

    $ALBO
    $AMYT
    $APGN
    $ARWR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for DAXXIFY issued to REVANCE THERAPEUTICS, INC.

    Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (SUPPL-2) with active ingredient DAXIBOTULINUMTOXINA-LANM has changed to 'Approval' on 08/11/2023. Application Category: BLA, Application Number: 761127, Application Classification:

    8/14/23 4:38:56 AM ET
    $RVNC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DAXXIFY issued to REVANCE THERAPEUTICS, INC.

    Submission status for REVANCE THERAPEUTICS, INC.'s drug DAXXIFY (ORIG-1) with active ingredient daxibotulinumtoixnA-lanm has changed to 'Approval' on 09/07/2022. Application Category: BLA, Application Number: 761127, Application Classification:

    9/8/22 1:11:06 PM ET
    $RVNC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BYLVAY issued to ALBIREO PHARMA INC

    Submission status for ALBIREO PHARMA INC's drug BYLVAY (ORIG-1) with active ingredient ODEVIXIBAT has changed to 'Approval' on 07/20/2021. Application Category: NDA, Application Number: 215498, Application Classification: Type 1 - New Molecular Entity

    7/21/21 11:28:05 AM ET
    $ALBO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALBO
    $AMYT
    $APGN
    $ARWR
    Financials

    Live finance-specific insights

    View All

    Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

    2025 Total Revenue of $233.8 million, up 16% from 2024; 2025 Product Revenue of $206.1 million, up 14% from 2024 Strengthened Financial Foundation Through Strong Commercial Execution and Disciplined Operational Management Cerus Corporation (NASDAQ:CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. "Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components," said William "Obi" Greenman, Cerus' pres

    3/2/26 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026

    Cerus Corporation (NASDAQ:CERS) announced today its fourth quarter and full-year 2025 financial results will be released on Monday, March 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay will

    2/17/26 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

    AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile), which holds multiple clinical-stage and late-stage program

    2/17/26 8:30:00 AM ET
    $ARWR
    $JNJ
    $MGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ALBO
    $AMYT
    $APGN
    $ARWR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Arrowhead Pharmaceuticals Inc.

    SC 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

    11/14/24 9:38:25 AM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cutera Inc.

    SC 13G/A - CUTERA INC (0001162461) (Subject)

    11/12/24 2:37:12 PM ET
    $CUTR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cerus Corporation

    SC 13G/A - CERUS CORP (0001020214) (Subject)

    11/12/24 9:53:11 AM ET
    $CERS
    EDP Services
    Technology

    $ALBO
    $AMYT
    $APGN
    $ARWR
    Leadership Updates

    Live Leadership Updates

    View All

    Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

    NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:  S&P MidCap 400 constituent Ciena Corp. (NYSE:CIEN) will replace Dayforce Inc. (NYSE:DAY) in the S&P 500, S&P SmallCap 600 constituent Arrowhead Pharmaceuticals Inc. (NASD: ARWR) will replace Ciena in the S&P MidCap 400, and ADT Inc. (NYSE:ADT) will replace Arrowhead Pharmaceuticals in the S&P SmallCap 600 effective prior to the opening of trading on Monday, February 9. Thoma Bravo L.P. acquired Dayforce in a deal that closed today.OneSpaWorld Holdings Ltd. (NASD: OSW) will replace Dynavax Technologies Corp. (NASD: DVAX) in the S&P SmallCap 600 effec

    2/4/26 6:15:00 PM ET
    $ADT
    $ARWR
    $CIEN
    Diversified Commercial Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. "Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans.

    4/15/25 4:00:00 PM ET
    $ARWR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

    NEW YORK, Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE:GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE:B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE:APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector January 27, 2025 S&P MidCap 400 Addition Guidewi

    1/22/25 5:54:00 PM ET
    $APO
    $ARWR
    $B
    Investment Managers
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care